INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,978 | +67.6% | 700 | 0.0% | 0.00% | – |
Q2 2023 | $7,742 | +92.2% | 700 | +133.3% | 0.00% | – |
Q1 2023 | $4,029 | -99.7% | 300 | -99.7% | 0.00% | -100.0% |
Q4 2022 | $1,449,516 | -17.2% | 117,180 | -6.6% | 0.02% | -21.1% |
Q3 2022 | $1,750,000 | +27.4% | 125,490 | +26.1% | 0.02% | +35.7% |
Q2 2022 | $1,374,000 | -15.3% | 99,500 | -0.3% | 0.01% | -12.5% |
Q1 2022 | $1,623,000 | -57.4% | 99,800 | -57.3% | 0.02% | -54.3% |
Q4 2021 | $3,808,000 | +10.7% | 233,800 | +0.9% | 0.04% | +16.7% |
Q3 2021 | $3,439,000 | -49.7% | 231,600 | -32.4% | 0.03% | -42.3% |
Q2 2021 | $6,842,000 | +24.2% | 342,645 | +43.5% | 0.05% | +13.0% |
Q1 2021 | $5,508,000 | -8.8% | 238,700 | -2.4% | 0.05% | +4.5% |
Q4 2020 | $6,037,000 | -33.4% | 244,471 | +11.9% | 0.04% | -45.7% |
Q3 2020 | $9,058,000 | +4.7% | 218,500 | +21.0% | 0.08% | -6.9% |
Q2 2020 | $8,651,000 | +23.7% | 180,612 | +62.6% | 0.09% | -14.7% |
Q1 2020 | $6,993,000 | -72.2% | 111,100 | -45.2% | 0.10% | -65.1% |
Q4 2019 | $25,118,000 | +84.0% | 202,700 | -1.5% | 0.29% | +68.8% |
Q3 2019 | $13,650,000 | +46.3% | 205,700 | +75.4% | 0.17% | +41.8% |
Q2 2019 | $9,333,000 | +34.4% | 117,300 | +88.9% | 0.12% | +28.4% |
Q1 2019 | $6,946,000 | +40.1% | 62,100 | +26.2% | 0.10% | +58.3% |
Q4 2018 | $4,958,000 | +125.6% | 49,200 | +182.8% | 0.06% | +130.8% |
Q3 2018 | $2,198,000 | -49.3% | 17,400 | -76.6% | 0.03% | -39.5% |
Q4 2017 | $4,334,000 | +42.3% | 74,207 | +41.3% | 0.04% | +30.3% |
Q3 2017 | $3,046,000 | +58.2% | 52,500 | +230.2% | 0.03% | +37.5% |
Q2 2017 | $1,925,000 | -54.4% | 15,900 | -57.4% | 0.02% | -63.1% |
Q1 2017 | $4,218,000 | +29.9% | 37,300 | +24.7% | 0.06% | +54.8% |
Q4 2016 | $3,248,000 | +218.4% | 29,900 | +382.3% | 0.04% | +180.0% |
Q3 2016 | $1,020,000 | – | 6,200 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |